1383716-40-2

Usage

Biological Activity

pik-iii is a vps34 inhibitor and is able to inhibit autophagy.vps34 kinase has been found to be responsible for synthesis and deposition of phosphatidylinositol-3-phosphate at autophagosome formation sites, resulting in the recruitment of ptdins(3)p-binding proteins.

in vitro

in previous study, pik-iii was identified as a selective inhibitor of vps34 binding in a hydrophobic pocket. in addition, pik-iii could acutely inhibit the autophagy and lipidation of lc3, which led to the stabilization of autophagy substrates. moreover, substrates such as ncoa4 were identified by conducting ubiquitin-affinity proteomic assay on pik-iii-treated cells, which accumulated in cells with atg7 deficience and co-localized with autolysosomes. ncoa4 could bind ferritin heavy chain-1 directly to target the iron-binding ferritin complex following starvation or iron depletion [1].

in vivo

animal study showed that pik-iii-treated ncoa4-/- mice had a profound accumulation of iron in splenic macrophages that were important for iron reutilization from engulfed red blood cells. in summary, such in vivo results provided a novel mechanism for selective autophagy of ferritin and revealed a previously untouched role for autophagy and ncoa4 in the control of in-vivo iron homeostasis [1].

IC 50

18 nm for vps34

references

[1] dowdle we et al. selective vps34 inhibitor blocks autophagy and uncovers a role for ncoa4 in ferritin degradation and iron homeostasis in vivo. nat cell biol. 2014 nov;16(11):1069-79.

Upstream product

• 504-24-5 4-aminopyridine 
• 1383716-81-1 4'-(cyclopropylmethyl)-2-(methylsulfinyl)-[4,5'-bipyrimidin]-2'-amine 
• 1383716-87-7 (3Z)-1-cyclopropyl-4-(dimethylamino)-3-[2-(pyridin-4-ylamino)pyrimidin-4-yl]but-3-en-2-one 
• 50-01-1 guanidine hydrochloride 

Relevant academic research and scientific papers

Pik3c3 inhibition promotes sensitivity to colon cancer therapy by inhibiting cancer stem cells

Background: Despite recent advances in therapies, resistance to chemotherapy remains a critical problem in the clinical management of colorectal cancer (CRC). Cancer stem cells (CSCs) play a central role in therapy resistance. Thus, elimination of CSCs is crucial for effective CRC therapy; however, such strategies are limited. Autophagy promotes resistance to cancer therapy; however, whether autophagy protects CSCs to promote resistance to CRC-therapy is not well un-derstood. Moreover, specific and potent autophagy inhibitors are warranted as clinical trials with hydroxychloroquine have not been successful. Methods: Colon cancer cells and tumoroids were used. Fluorescent reporter-based analysis of autophagy flux, spheroid and side population (SP) culture, and qPCR were done. We synthesized 36-077, a potent inhibitor of PIK3C3/VPS34 kinase, to inhibit autophagy. Combination treatments were done using 5-fluorouracil (5-FU) and 36-077. Results: The 5-FU treatment induced autophagy only in a subset of the treated colon cancer. These autophagy-enriched cells also showed increased expression of CSC markers. Co-treatment with 36-077 significantly improved efficacy of the 5-FU treatment. Mechanistic studies revealed that combination therapy inhibited GSK-3β/Wnt/β-catenin signaling to inhibit CSC population. Conclusion: Autophagy promotes resistance to CRC-therapy by specifically promoting GSK-3β/Wnt/β-catenin signaling to promote CSC survival, and 36-077, a PIK3C3/VPS34 inhibitor, helps promote efficacy of CRC therapy.

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo

Autophagy is a dynamic process that regulates lysosomal-dependent degradation of cellular components. Until recently the study of autophagy has been hampered by the lack of reliable pharmacological tools, but selective inhibitors are now available to modulate the PI 3-kinase VPS34, which is required for autophagy. Here we describe the discovery of potent and selective VPS34 inhibitors, their pharmacokinetic (PK) properties, and ability to inhibit autophagy in cellular and mouse models.

BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS

The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods